Released Mar 30, 2026, before the open
10-K filed Mar 30, 2026, 89 days after period end · 0001628280-26-022010
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$37.39M-$37.39M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$41,122,000N/M
Operating Cash Flowderived-$23,886,000N/M
Free Cash Flowderived-$24,124,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|---|
| Net Income | -$37.39M | -$20.96M | -$12.44M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR